Compare Moderna, Inc. (MRNA) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Newmont Corporation — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Newmont Corporation trades at $117.84 (market cap $121.75B). The key difference: Newmont Corporation is the larger of the two by market cap, and Newmont Corporation pays a 0.9% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Newmont Corporation for 58 Days on average.
| MRNA | NEM | |
|---|---|---|
Market Cap | $78.65B | $121.75B |
Volume | 37,373,437 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $203.46 | $135.14 |
52-Week Low | $22.36 | $78.63 |
Typical Hold Time | 59 Days | 58 Days |
Enterprise Value | $74.80B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Newmont Corporation (NEM) trades at $115.55, up 1.77% with strong fundamental performance including record free cash flow of $5.3B in H1 2026 and three consecutive earnings beats. The stock shows bearish technical signals despite solid valuation metrics with P/E of 14.57 and ROE of 25.53%. Recent news highlights operational improvements and gold price support driving per-share growth initiatives.
NEM presents a compelling value opportunity with strong analyst consensus (75.68% buy rating) and $136.83 price target representing 18% upside. Key risks include gold price volatility and execution of growth projects, but robust cash flow generation and improving margins support long-term shareholder value creation in the current gold market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
